Aspergillosis - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 108
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AA0717079B6EN
Leaflet:

Download PDF Leaflet

Aspergillosis - Pipeline Review, H2 2016
Aspergillosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis – Pipeline Review, H2 2016, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 18, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.Aspergillosis.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Aspergillosis Overview
Therapeutics Development
Pipeline Products for Aspergillosis - Overview
Pipeline Products for Aspergillosis - Comparative Analysis
Aspergillosis - Therapeutics under Development by Companies
Aspergillosis - Therapeutics under Investigation by Universities/Institutes
Aspergillosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Aspergillosis - Products under Development by Companies
Aspergillosis - Products under Investigation by Universities/Institutes
Aspergillosis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals, Inc.
Astellas Pharma Inc.
Biomar Microbial Technologies
Biosergen AS
Cidara Therapeutics, Inc.
F2G Ltd
Hsiri Therapeutics LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings, Inc.
Merck & Co., Inc.
Nanomerics Ltd
Novabiotics Limited
Pulmatrix, Inc.
Pulmocide Ltd
Scynexis, Inc.
Sealife PHARMA GMBH
Sigma-Tau S.p.A.
TGV-Laboratories
Vical Incorporated
Aspergillosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-9726 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspergillus fumigatus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSG-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celastrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-901318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-425796C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDN-0018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-339 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PC-945 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
posaconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCY-078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Aspergillosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Aspergillosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Invasive Aspergillosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VL-2397 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspergillosis - Dormant Projects
Aspergillosis - Discontinued Products
Aspergillosis - Product Development Milestones
Featured News & Press Releases
Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS
Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH
Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis
Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
Jan 06, 2016: FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis
Dec 17, 2015: Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
Nov 30, 2015: F2G to Participate in the Adaptive Pathways Pilot Programme
Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015
Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397
Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 108

LIST OF TABLES

Number of Products under Development for Aspergillosis, H2 2016
Number of Products under Development for Aspergillosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016
Aspergillosis - Pipeline by Astellas Pharma Inc., H2 2016
Aspergillosis - Pipeline by Biomar Microbial Technologies, H2 2016
Aspergillosis - Pipeline by Biosergen AS, H2 2016
Aspergillosis - Pipeline by Cidara Therapeutics, Inc., H2 2016
Aspergillosis - Pipeline by F2G Ltd, H2 2016
Aspergillosis - Pipeline by Hsiri Therapeutics LLC, H2 2016
Aspergillosis - Pipeline by iCo Therapeutics Inc., H2 2016
Aspergillosis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
Aspergillosis - Pipeline by Merck & Co., Inc., H2 2016
Aspergillosis - Pipeline by Nanomerics Ltd, H2 2016
Aspergillosis - Pipeline by Novabiotics Limited, H2 2016
spergillosis - Pipeline by Pulmatrix, Inc., H2 2016
Aspergillosis - Pipeline by Pulmocide Ltd, H2 2016
Aspergillosis - Pipeline by Scynexis, Inc., H2 2016
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H2 2016
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H2 2016
Aspergillosis - Pipeline by TGV-Laboratories, H2 2016
Aspergillosis - Pipeline by Vical Incorporated, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Aspergillosis - Dormant Projects, H2 2016
Aspergillosis - Discontinued Products, H2 2016 95

LIST OF FIGURES

Number of Products under Development for Aspergillosis, H2 2016
Number of Products under Development for Aspergillosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Aspergillosis - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Idiopathic Short Stature - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 36 pages
Gastroenteritis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 49 pages
Bacterial Pneumonia - Pipeline Review, H2 2014 US$ 1,500.00 Aug, 2014 · 55 pages

Ask Your Question

Aspergillosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: